ClinicalTrials.gg
RecruitingNCT06155604Updated Dec 16, 2024

SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

A Phase 2 interventional study of Dapagliflozin 10mg Tab and Standard maintenance therapy in Lupus Nephritis and Chronic Kidney Diseases, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by The University of Hong Kong · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Lupus Nephritis with a site in Hong Kong — 3 open to participants now, 4 under way, 2 of them phase 3. Lupus Nephritis · Hong Kong.

Planned enrollment
7th of 18
150 · median 104
Started
2023
the only one that year
Phase 2
8 of 19
1 open now
Registered
18th of 19
by date
Lead sponsor
5 of 19
The University of Hong Kong

Among the 19 studies in Lupus Nephritis with a site in Hong Kong, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 8 in phase 2, and was the 18th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

3 of the 19 studies in Lupus Nephritis with a site in Hong Kong are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lupus Nephritis with a site in Hong Kong, or all of them as a file.
02

Study summary

Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). Although the standard-of-care treatments for active severe LN are effective, a substantial proportion of LN patients still develop CKD and eventually end-stage kidney disease (ESKD).

Cardiovascular complications are common and is a leading cause of death in SLE and LN patients. It is well recognized that LN patients had multiple risk factors for cardiovascular complications such as diabetes mellitus (DM), dyslipidaemia and vascular inflammation. Sodium-glucose co-transporter 2 (SGLT2) inhibitor are initially developed as an oral anti-diabetic agent and has shown to be effective in glycaemic control, has benefits in lipid metabolism, cardiovascular and renal outcomes, and also well tolerated by patients. Various trials have also demonstrated the benefits of SGLT2 inhibitor in the reduction of CKD, ESKD, and renal or cardiovascular death. However, the effect of SGLT2 inhibitor in LN remains unclear.

The purpose of this study is to investigate the effect of SGLT2 on renal outcomes in LN patients with CKD, as well as the side effects, metabolic profiles, immunological functions and disease stability.

Read the detailed description

Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). The standard-of-care treatments for active severe LN are high-dose corticosteroids in combination with mycophenolate mofetil (MMF) or cyclophosphamide (CYC), followed by low-dose corticosteroids with either MMF or azathioprine (AZA) as maintenance therapy. While these immunosuppressive treatments are effective in mitigating active nephritis and preventing relapses in most patients, a substantial proportion of LN patients still develop CKD and eventually end-stage kidney disease (ESKD). CKD and ESKD are often a result of cumulative kidney damage due to a severe episode of LN or repeated renal flares. Indeed, preserving renal function in LN is important because renal failure confer a 26-fold risk of mortality compared to age- and sex-matched general population. The current mainstay of treatment for stable LN with CKD is renin-angiotensin system (RAS) blockade, and yet a considerable number of patients still show progressive CKD and eventually ESKD despite these reno-protective measures. Therefore, novel therapeutic approaches are needed to optimize the renal outcomes of LN patients with CKD.

Sodium-glucose co-transporter 2 (SGLT2) inhibitor are initially developed as an oral anti-diabetic agent and has rapidly gained popularity in diabetes mellitus (DM) management due to its efficacy in glycaemic control, benefits in cardiovascular and renal outcomes and also generally favourable tolerability. In Type 2 DM patients, the EMPA-REG OUTCOME, CANVAS and CREDENCE trials have all demonstrated the benefits of SGLT2 inhibitor in various renal and cardiovascular endpoints including the reduction of incident nephropathy, development of CKD and ESKD, and renal or cardiovascular death. These landmark trials have established SGLT2 inhibitor a first-line treatment for diabetic kidney disease. Importantly, the DAPA-CKD study further showed that dapagliflozin treatment in CKD patients was associated with lower risk of sustained decline in eGFR of at least 50%, ESKD, or death from renal or cardiovascular causes, irrespectively of the presence of absence of DM. The benefits of SGLT2 inhibitor have also been shown in some glomerular diseases such as IgA nephropathy and focal segmental glomerulosclerosis. The use of SGLT2 inhibitors was associated with reduction in proteinuria, which is a robust predictor for renal progression in various glomerular pathologies. The effect of SGLT2 inhibitor in LN, however, remains elusive because all previous RCTs have excluded patients with SLE or LN.

Cardiovascular complications common and a leading cause of death in SLE and LN patients. It is well recognized that LN patients had multiple risk factors for cardiovascular complications such as DM, dyslipidaemia and vascular inflammation. Indeed, SLE and LN patients showed increased propensity for DM because of the prevalent use of corticosteroids and increased insulin resistance related to chronic inflammation. Previous studies suggested that SGLT2 inhibition can effectively improve glycaemic profiles in type 2 DM patients, and also prevent the development of new onset DM in CKD patients. Other studies have also indicated the beneficial effects of SGLT2 inhibitors on lipid metabolism via reduction in visceral fat accumulation, regulation of serum lipoprotein levels, decrease in lipid oxidation and shifting of substrate utilization. The investigators postulate that SGLT2 inhibitors in LN patients with CKD can attenuate the glycaemic and lipid profiles, and hence reduce long-term cardiovascular complications and hence long-term clinical outcomes.

Long-term clinical outcomes of LN patients are also heavily affected by renal relapse, as this will cause attribution of nephron mass and hence progressive renal failure. Recurrent renal flares will also require repeated administration of intensive immunosuppression, leading to increased cumulative treatment toxicities. Therefore, therapies other than maintenance immunosuppression that can enhance disease stability would be clinically useful. Disease stability in LN is related to immunological abnormality, efficacy of maintenance therapy and also drug compliance. In this context, the B cell repertoire plays pivotal roles in the pathogenesis of SLE and LN including the production of pathogenic autoantibodies, presentation of autoantigens and secretion of pro-inflammatory cytokines. Previous studies have reported increased circulating memory B cells and reduced naïve B cells in SLE patients. The expansion of memory B cells increases the propensity for disease relapse because these B cell subtypes are less vulnerable to conventional cell cycle-dependent immunosuppressive drugs and can be easily reactivated upon stimulation. Investigators' previous studies also demonstrated that LN patients with multiple relapses showed significantly higher memory-to-naïve B cell ratio compared to those without relapse. Furthermore, dysregulation of B cell signatures (miR-148a, BACH1, BACH2) in memory B cell is related to disease relapse in LN patients. miRNA-148a plays a significant role in B cell development, and its upregulation has been observed in B cells, T cells and tissue lesions in patients and mice with SLE. Other researchers have reported that increased miRNA-148a expression can inhibit Gadd45a, Bim and PTEN and prevent apoptosis of immature B lymphocytes, resulting in enhanced B cell auto-reactivity. BACH1 and BACH2 are important transcription factors in B cells that are regulated by miRNA-148a, and they exert inhibitory effects on B cell differentiation and homeostasis. Other investigators have reported decreased BACH2 expression in B cells isolated from SLE patients, and transfection of BACH2 into B lymphocytes from lupus patients suppressed their proliferation and promoted apoptosis. A recent GWAS analysis also identified BACH2 as a novel susceptibility locus in Chinese SLE patients. The effect of SGLT2 inhibitor on immune system and disease activity in SLE and LN patients, however, remains unknown. The investigators' bioinformatic analyses using public domain data showed that there was significant correlation between circulating memory B cells and SGLT2 expression LN patients. Based on these observations and the investigators' pilot bioinformatics data, the investigators hypothesize that SGLT2 inhibition may also modulate disease stability in LN patients via its effect on memory B cells and related cellular signatures.

Given these backgrounds, the investigators propose an open-label RCT to investigate the effect of SGLT2 on renal outcomes, metabolic profiles and immunological parameters in LN patients with CKD.

03

Conditions studied

  • Lupus Nephritis
  • Chronic Kidney Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with -proven Class III or IV or V LN according to the ISN/RPS 2003 classification
  2. Patients with CKD ( 15-60mL/min)
  3. Patients in quiescent disease (defined as SLEDAI score \<4 with no points in the renal domain)
  4. Patients on a stable dose of prednisolone (PRED 5-7.5 mg/D) alone or in combination with MMF (\<=1.5 g/D) or AZA (\<=150 mg/D) in the past 3 months

Exclusion criteria

Exclusion Criteria:

  1. Patients with -proven glomerulonephritis other than LN or hereditary kidney diseases
  2. Patients with type 1 diabetes mellitus (DM)
  3. Patients with stage 5 CKD or ESKD on renal replacement therapy
  4. Patients with frequent urinary tract infections
  5. Patients with history of ketoacidosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Treatment group

    standard maintenance therapy plus dapagliflozin 10 mg daily

    Drug: Dapagliflozin 10mg Tab · Drug: Standard maintenance therapy

  • Other
    Control group

    standard maintenance therapy only

    Drug: Standard maintenance therapy

Interventions

06

What researchers measure

Primary outcomes

  1. eGFR reduction

    Incidence of eGFR reduction by 30% or more at 24 months

    Time frame: 24 months

Secondary outcomes

  1. eGFR

    Changes in eGFR over time

    Time frame: 24 months

  2. Urine protein-to-creatinine (UPC) ratio

    Changes in urine protein-to-creatinine (UPC) ratio over time

    Time frame: 24 months

  3. End-stage kidney disease (ESKD)

    Incidence rates of end-stage kidney disease (ESKD)

    Time frame: 24 months

  4. Fasting glucose

    Changes in fasting glucose over time

    Time frame: 24 months

  5. Hba1c

    Changes in Hba1c over time

    Time frame: 24 months

  6. Lipids

    Changes in lipids over time

    Time frame: 24 months

  7. Anti-dsDNA

    Changes in anti-dsDNA over time (measured by ELIZA)

    Time frame: 24 months

  8. C3

    Changes in C3 over time (measured by nephelometry)

    Time frame: 24 months

  9. Memory B cells

    Changes in memory B cells over time (measured by flow cytometry)

    Time frame: 24 months

  10. miR-148a

    Changes in miR-148a over time (measured by qPCR using blood samples)

    Time frame: 24 months

  11. BACH1

    Changes in BACH1 over time (measured by qPCR using blood samples)

    Time frame: 24 months

  12. BACH2

    Changes in BACH2 over time (measured by qPCR using blood samples)

    Time frame: 24 months

  13. PAX5

    Changes in PAX5 over time (measured by qPCR using blood samples)

    Time frame: 24 months

  14. Clinical relapses

    Occurrence of clinical relapses (renal and extra-renal relapses)

    Time frame: 24 months

  15. Urinary tract infection

    Incidence rates of urinary tract infection

    Time frame: 24 months

  16. Ketoacidosis

    Incidence rates of ketoacidosis

    Time frame: 24 months

  17. genital infection

    Incidence rates of genital infection

    Time frame: 24 months

  18. Acute kidney injury

    Incidence rates of acute kidney injury

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Dec 4, 2023
StartActual
Jan 4, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06155604
Responsible party
Dr. Desmond Yat-Hin Yap (Clinical Associate Professor, The University of Hong Kong) — Principal investigator
First posted
Dec 4, 2023
Start date
Jan 4, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 16, 2024

Study contacts

Desmond Yap, MD (HK)
Contact
desmondy@hku.hk
85222554385
Desmond Yap, MD (HK)
principal investigator · The University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion